Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 8Leukemia, Myeloid, Acute 7Leukemia, Myelomonocytic, Chronic 5Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Melanoma 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Cytopenia 1Carcinoma, Squamous Cell 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Brentuximab Vedotin 21Cyclophosphamide 20fludarabine 16Rituximab 13Lenalidomide 13Dexamethasone 12fludarabine phosphate 10Melphalan 10Busulfan 10Mycophenolic Acid 9pirtobrutinib 7dacetuzumab 7Whole-Body Irradiation 7Tacrolimus 7Bortezomib 7Doxorubicin 6Azacitidine 6ruxolitinib 5Vincristine 5Prednisone 5Imatinib Mesylate 5Bone Marrow Transplantation 5ponatinib 4pomalidomide 4Mesna 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Blood Specimen Collection 4Bendamustine Hydrochloride 4venetoclax 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × cedazuridine × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡